Market Research Logo

IDO Inhibitors - A Pipeline Analysis Report

IDO Inhibitors - A Pipeline Analysis Report

IDO inhibitors: An insight

The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.

A few large pharmaceutical companies are investing billions of dollars through multiple collaboration agreements for the R&D for IDO inhibitors. The synergistic effects of IDO inhibitors with chemotherapy together may create a new opportunity for vaccines and immunotherapy. The combination of IDO inhibitors with vaccines can redefine the cancer treatment in coming years if everything goes in the right direction as per the initial results.

Covered in this report

The report covers the present scenario and the growth prospects of the IDO inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's IDO Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Pfizer
  • Bristol-Myers Squibb
  • Kyowa Hakko Kirin
  • Key questions answered in this report
    • How will the market evolve during the forecast period?
    • What are the major parameters impacting the market?
    • What are the key market trends?
    • What are the challenges to market growth?
    • Who are the key companies in this market space?


    Press Release

    Technavio Announces the Publication of its Research Report - IDO Inhibitors - A Pipeline Analysis Report

    Technavio recognizes the following companies in the IDO inhibitors: Pfizer, Bristol-Myers Squibb, and Kyowa Hakko Kirin.

    Indoleamine-2,3-dioxygenase (IDO) is one of the several immune checkpoints involved in tumor immune escape. It is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along with the kynurenine pathway. By inhibiting IDO, researchers hope to restore immune system responses so that cancer cells can be more easily identified and destroyed.

    As most of the IDO inhibitors are currently in the very nascent stage, predicting the future is not sensible at this point of time. However, if it succeeds to enter the market in coming years, then IDO inhibitors may not only transform the way to treat advanced melanoma, but also how the treatment for non-small lung cancer, triple-negative breast cancer, and bladder cancer are being carried out with the existing therapies. Most likely that would be huge news for the researchers and the patients as well.

    The global IDO inhibitors market is still to witness its first approval for the various type of solid tumors. The majority of the pipeline molecules are still in pre-clinical stage, a few being in Phase II, and only one candidate made its way to Phase III stage of development so far.

    Companies Mentioned

    Pfizer, Bristol-Myers Squibb, and Kyowa Hakko Kirin.

    • Executive summary
    • Scope of the report
    • Research methodology
    • IDO inhibitors: An insight
      • Introduction
        • Table Overview of collaboration agreements in global IDO inhibitors market 2017
    • Regulatory framework
      • US
        • Table Drug approval process by US FDA
      • Europe
      • Japan
      • Australia
      • China
    • Pipeline landscape
      • Table Pipeline landscape
      • Table Pipeline molecules by vendors
    • Comparative analysis
      • Table Pipeline molecules by numbers
      • Table Pipeline molecules by percentage
      • Late-stage molecule (Phase III)
        • Table Overview: Epacadostat
        • Table Clinical trials description of epacadostat
      • Mid-stage molecule (Phase II)
        • Table Overview: Indoximod
        • Table Clinical trials description of indoximod
      • Early-stage molecules (Phase I/II and I)
        • Table Overview: BMS-986205
        • Table Clinical trials description of BMS-986205
        • Table Overview: Navoximod
        • Table Clinical trials description of navoximod
        • Table Overview: PF 06840003
        • Table Clinical trials description of PF-06840003
        • Table Overview: KHK2455 oral
        • Table Clinical trials description of KHK2455 oral
        • Table Overview: NLG802
        • Table Clinical trials description of NLG802
      • Pre-clinical and discovery stage molecules
        • Table Overview: IDO inhibitor
        • Table Overview: GBV1012
        • Table Overview: GBV1028
        • Table Overview: RG70099
        • Table Overview: IDO inhibitor
        • Table Overview: IDO1 inhibitor
        • Table Overview: Dual IDO1/TDO inhibitor
        • Table Overview: IDO-1 inhibitor
        • Table Overview: dCellVax
        • Table Overview: IDO1 Inhibitor
        • Table Overview: Covalent IDO inhibitors
      • Inactive molecules
        • Table Dormant Products,2017
    • Indication analysis
      • Table Analysis by indication
      • Table An overview of top five indications (courtesy
    • Therapeutic assessment by therapy
      • Therapeutic assessment based on therapy
        • Table Assessment of pipeline products by therapy
    • Therapeutic assessment by RoA
      • Therapeutic assessment based on RoA
        • Table Assessment by RoA
    • Therapeutic assessment by molecule type
      • Therapeutic assessment based on molecule type
        • Table Assessment by molecule type
        • Table Assessment of molecule types in various stages
    • Key companies
      • Active companies: Category and parameters
        • Table Active companies: Category and parameters 2017
        • Table Segmentation of companies
        • Table Overview: Aurigene Discovery Technologies 2017
        • Table Overview: Bristol-Myers Squibb 2017
        • Table Overview: Curadev Pharma 2017
        • Table Overview: Globavir Biosciences 2017
        • Table Overview: Incyte Corporation 2017
        • Table Overview: IOmet Pharma 2017
        • Table Overview: Kyowa Hakko Kirin 2016
        • Table Overview: Netherlands Translational Research Center (NTRC) 2017
        • Table Overview: NewLink Genetics Corporation 2017
        • Table Overview: Pfizer 2017
        • Table Overview: Redx Pharma 2017
        • Table Overview: Ensemble Therapeutics 2017
        • Table Overview: Regen BioPharma 2017
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report